Expert neurologists provide an overview of disease modifying agents that alter the course of MS. Examples include interferon-beta, glatiramer acetate, mitoxantrone, natalizumab, teriflunomide, fingolimod, and dimethyl fumarate. The experts also talk about how these drugs are administered and emphasize that it is important for patients to discuss with their physicians how to best choose the right therapy that will balance the benefits of a given drug treatment against any potential risks or side effects.

Patients with MS talk about their personal experiences with disease modifying therapies, and how they feel about staying on them even if benefits are not immediately apparent.